Moderna News - January 22, 2026

Moderna CEO Stephane Bancel Announces Halt to New Late-Stage Vaccine Trial Investment

Moderna announced a major strategic pivot, ceasing investment in new late-stage vaccine trials and instead redirecting capital toward its oncology and heart...

🟢 Moderna is trading 3% up today on continued momentum from cancer vaccine data

MRNA is trading at $51.30 (+2.99%) amid ongoing gains after strong five-year Phase 2b data showed its personalized mRNA cancer therapy combined with Keytruda...